Family Capital Trust Co Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Family Capital Trust Co lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.5% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 39,839 shares of the company’s stock after selling 218 shares during the period. Johnson & Johnson accounts for approximately 1.9% of Family Capital Trust Co’s portfolio, making the stock its 12th biggest holding. Family Capital Trust Co’s holdings in Johnson & Johnson were worth $5,931,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Dempze Nancy E lifted its holdings in Johnson & Johnson by 0.4% in the 2nd quarter. Dempze Nancy E now owns 20,907 shares of the company’s stock valued at $2,939,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Johnson & Johnson by 10.3% in the 2nd quarter. Bessemer Group Inc. now owns 268,577 shares of the company’s stock valued at $37,769,000 after purchasing an additional 25,097 shares in the last quarter. Private Asset Management Inc. lifted its holdings in Johnson & Johnson by 0.5% in the 2nd quarter. Private Asset Management Inc. now owns 93,956 shares of the company’s stock valued at $13,213,000 after purchasing an additional 425 shares in the last quarter. Martin Investment Management LLC raised its holdings in shares of Johnson & Johnson by 5.1% during the 2nd quarter. Martin Investment Management LLC now owns 32,745 shares of the company’s stock worth $4,605,000 after acquiring an additional 1,586 shares during the period. Finally, LVM Capital Management Ltd. MI raised its holdings in shares of Johnson & Johnson by 4.3% during the 3rd quarter. LVM Capital Management Ltd. MI now owns 125,397 shares of the company’s stock worth $18,669,000 after acquiring an additional 5,225 shares during the period. Institutional investors own 67.44% of the company’s stock.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.

Several research firms have recently commented on JNJ. Credit Suisse Group lifted their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a report on Wednesday. Cantor Fitzgerald lifted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday. SVB Leerink reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. Finally, Independent Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the stock from $161.00 to $164.00 in a report on Monday, July 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $164.93.

NYSE JNJ opened at $148.10 on Friday. The company has a market cap of $389.92 billion, a P/E ratio of 23.29, a P/E/G ratio of 3.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The stock has a 50-day moving average of $148.57 and a two-hundred day moving average of $146.59. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. Johnson & Johnson’s revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.12 EPS. On average, analysts anticipate that Johnson & Johnson will post 8 EPS for the current fiscal year.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: How to Invest in a Bull Market

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.